Bibliography

BIBLIOGRAPHY
1. Mandell LA, Wunderink R. Pneumonia, Chapter 257, In: Longo DL et al.
Harrison's principles of Internal medicine 18th edition, New York, McGraw Hill
companies, 2011, p: 2130-2141.
2. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of
America. American Thoracic Society. Infectious Diseases Society of merica /
American Thoracic Society consensus guidelines on the management of
community-acquired pneumonia in adults. Clinical Infectious Disease. 2007; 44
Supplement 2:S27-72.
3. Lim WS, Baudouin SV, George RC, et al The British Thoracic Society
Guidelines for the management of Community acquired pneumonia in adults:
Update 2009. Thorax Volume 64, Supplement III, p: 7.
4. Corrales-Medina VF, Suh KN, Rose G, et al. Cardiac complications in patients
with community- acquired pneumonia: a systematic review and meta-analysis of
observational studies. PLoS Med, 2011,8(6): el001048.
5. Santhos-Gallego CG, Juan J, Badimon. The sum of two evils: Pneumonia and
Myocardial Infarction: is platelet activation the missing link? J Am Coll Cardiol.
2014: 64(18): 1926-1928.
6. Mandell LA, Niederman M. The Canadian Community- Acquired Pneumonia
Consensus Conference Group. Antimicrobial treatment of community-acquired
pneumonia in adults: A conference report. Can J Infect Dis 1993;4:25.
7. Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult
lower respiratory tract infections: Summary. European Respiratory Journal 2005;
26:1138-1180.
8. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients
with community-acquired pneumonia. N Eng J Med. 1997; 336(4): 243-250.
9. Musher DM. Streptococcus pneumoniae. In: Mandell GL, Bennett JE, Dolin R,
eds. Mandell, Douglass and Bennett's principles and practice of infectious
diseases. Philadelphia: Churchill Livingstone, 2005: 2392-411.
10. Woodhead M. Assessment of illness severity in community acquired pneumonia:
A useful new prediction tool? Thorax 2003;58:371-2
11. Menendez R, Torres A, Zalacain R, et al. Risk factors of treatment failure in
community acquired pneumonia: Implications for disease outcome. Thorax 2004;
59:960-5.

80

Bibliography
12. Ruiz M, Ewig S, Torres A, et al. Severe community-acquired pneumonia- Risk
factors and follow up epidemiology. Am J Respir Crit Care Med 1999; 160(3): 923-9.
13. Paganin F, Lilienthal F, Bourdin A, et al. Severe community acquired pneumonia:
assessment of microbial etiology as mortality factor. European Respiratory
Journal.2004; 24: 779-85.
14. Sligl WI, Eurich DT, Marrie TJ, et al. Age still matters: Prognosticating shortand long- term mortality for critically ill patients with pneumonia. Crit Care
Med. 2010; 38(11):2126-2132. [PubMed: 20818232],
15. Bello S, Lasierra AB, Minchole E, et al. Prognostic power of Proadrenomedullin
in community acquired pneumonia is independent of etiology. European
Respiratory Journal. 2012; 39:1144-1155. [PubMed: 22075489]
16. Kruger S, Ewig S, Giersdorf S, et al. Cardiovascular and inflammatory
biomarkers to predict short and long term survival in community acquired
pneumonia: results from the German Competence Network, CAPNETZ. Am J
Respir Crit Care Med. 2010; 182:1426-1434. [PubMed: 20639437],
17. Cannon CP, Braunwald E. Unstable angina and Non ST segment elevated
Myocardial Infarction, chapter 244, In: Longo DL et al, Harrison's principles of
Internal medicine, 18th edition, New York, McGraw Hill companies, 2011, p2015-2021.
18. Cannon CP, McCabe CH, Stone PH, et al. The electrocardiogram predicts one
year outcome of patients with unstable angina and non-Q wave myocardial
infarction: results of the TIMI III Registry ECG Ancillary Study. J Am Coll
Cardiol. 1997; 30(1): 133-140.
19. Hyde TA, French JK, Wong CK, et al. Four-year survival of patients with acute
coronary syndromes without ST- segment elevation and prognostic significance
of 0.5-mm ST-segment depression. Am J Cardiol.1999; 84(4):379-385.
20. Mauri F, Franzosi MG, Maggioni AP, et al. Clinical value of 12-lead
electrocardiography to predict the long term prognosis of GISSI-1 patients. J Am
Coll Cardiol. 2002;39(10): 1594-1600
21. Morrow DA, Rifai N, Antman EM, et al. C reactive protein is a potent predictor of
mortality independently of and in combination with troponin T in acute coronary
syndromes: A TIMI 11A sub study. J Am Coll Cardiol. 1998; 31(7): 1460-1465.
22. Cannon CP, McCabe CH, Wilcox RG, et al. Association of white blood cell count
with increased mortality in acute myocardial infarction and unstable angina
81

Bibliography
pectoris. OPUS-TIMI 16 Investigators. Am J Cardiol. 2001; 87(5):636-639, A10.
23. Sabatine MS, Morrow DA, Cannon CP, et al. Relationship between baseline
white blood cell count and degree of coronary artery disease and mortality in
patients with acute coronary syndromes: a TACTICS-TIMI 18 sub- study. J Am
Coll Cardiol. 2002; 40(10): 1761-1768.
24. Baldus S, Heeschen C, Meinertz T, et al. Myeloperoxidase serum levels predict
risk in patients with acute coronary syndromes. CAPTURE Investigators.
Circulation. 2003, 108(12): 1440-1445.
25. James SK, Lindahl B, Siegbahn A, et al. N terminal pro brain natriuretic peptide
and other risk markers for the separate prediction of mortality and subsequent
myocardial infarction in patients with unstable coronary artery disease: A Global
Utilization of Strategies to Open occluded arteries (GUSTO)-IV sub study.
Circulation. 2003; 108(3):275-281. Epub 2003 Jul 7.
26. De Lemos JA, Morrow DA, Bentley JH, et al. The prognostic value of B-type
natriuretic peptide in patients with acute coronary syndromes. New England
Journal of Medicine. 2001;345(14):1014- 1021
27. Mega JL, Morrow DA, De Lemos JA, et al. B-type natriuretic peptide at
presentation and prognosis in patients with ST-segment elevation myocardial
infarction: An ENTIRE-TIMI-23 sub study. J Am Coll Cardiol. 2004; 44(2):335339.
28. Arakawa N, Nakamura M, Aoki H, et al. Relationship between plasma level of
brain natriuretic peptide and myocardial infarct size. Cardiology. 1994;
85(5):334-340.
29. Sabatine MS, Morrow DA, de Lemos JA, et al. Multi marker approach to risk
stratification in non ST elevation acute coronary syndromes: Simultaneous
assessment of troponin I, C-reactive protein, and B-type natriuretic peptide.
Circulation. 2002;105(15):1760-1763
30. Antan EM, Cohen M, Berink PJ, et al. The TIMI risk score for unstable angina or
non ST elevation MI: A method for prognostication and therapeutic decision
making. JAMA 2000; 284: 835-842.
31. Boersma E, Pieper KS, Steyerberg EW, et al. Predictors of outcome in patients
with acute coronary syndrome without ST segment elevation. Results from an
international trial of 9461 patients. The PURSUIT investigators. Circulation
2000; 101: 2557-67.
32. Granger CB, Golberg RJ, Dabbous O, et al. Predictors of hospital mortality in the
82

Bibliography
global registry of acute coronary events. Arch Intern Med 2003; 163:2345-53.
33. Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC Guideline for
the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes:
Executive Summary. A Report of the American College of Cardiology/American
Heart Association Task Force on Practice Guidelines. Circulation 2014;
130:2354-2394.
34. Heeschen C, Hamm CW, Goldmann B, et al. Troponin concentrations for
stratification of patients with acute coronary syndromes in relation to therapeutic
efficacy of tirofiban. PRISM Study Investigators. Lancet. 1999; 354(9192):
1757-1762.
35. Corrales-Medina VF, Suh KN, Rose G, et al. Cardiac complications in patients
with community acquired pneumonia: A systematic review and meta-analysis of
observational studies. PloS Med 2011;8: el001048.
36. Fry AM, Shay DK, Holman RC, et al. Trends in hospitalizations for pneumonia
among persons aged 65 years or older in the United States, 1988-2002. JAMA,
2005; 294: 2712-2719.
37. Jones DL, Adams RJ, Brown TM, et al. Heart disease and stroke statistics-2010
update: A report from the American Heart Association. Circulation. 2010; 121:
e46-e215
38. Fine MJ, Smith MA, Carson CA, et al. Prognosis and outcomes of patients with
community- acquired pneumonia. A meta- analysis. JAMA.1996; 275: 134-141.
39. Hedlund JU, Ortqvist AB, Kalin ME, et al. Factors of importance for the long
term prognosis after hospital treated pneumonia. Thorax. 1993; 48:785-789.
[PubMed: 8211867]
40. Corrales-Medina VF, Serpa J, Rueda AM, et al. Acute bacterial pneumonia is
associated with the occurrence of acute coronary syndromes. Medicine
(Baltimore), 2009, 88(3): 154-159.
41. Ramirez J, Aliberti S, Mirsaeidi M, et al. Acute myocardial infarction in
hospitalized patients with community-acquired pneumonia, 2008 Clinical
Infectious Diseases. 47(2): 182-187.
42. Becker T, Moldoveanu A, Cukierman T, et al. Clinical outcomes associated with
the use of subcutaneous insulin by glucose sliding scales to manage
hyperglycemia in hospitalized patients with pneumonia. Diabetes Res Clin Pract,
2007, 78(3): 392-397.
43. United States Census Bureau. 2008 National Population Projections. Washington
83

Bibliography
(D.C): U.S. Census Bureau.
44. Khand AU, Gemmell I, Rankin AC, et al. Clinical events leading to the
progression of heart failure: insights from a national database of hospital
discharges. European Heart Journal.2001, 22: 153-164.
45. Corrales-Medina VF, Madjid M, Musher DM. Role of acute infection in
triggering acute coronary syndromes. Lancet Infect Dis. 2010, 10(2): 83-92.
46. Wattigney WA, Mensah GA, Croft JB. Increasing trends in hospitalization for
atrial fibrillation in the United States, 1985 through 1999: Implications for
primary prevention. Circulation.2003, 108: 711-716
47. Bainton D, Jones GR, Hole D. Influenza and ischaemic heart disease: a possible
trigger for acute myocardial infarction? Int J Epidemiol. 1978; 7:231-239.
48. Blasi F, Cosentini R, Raccanelli R, et al. A possible association of Chlamydia
pneumonia infection and acute myocardial infarction in patients younger than 65
years of age. Chest 1997; 112(2):309-12.
49. Meier CR, Jick SS, Derby LE, et al. Acute respiratory tract infections and risk of
first-time acute myocardial infarction. Lancet 1998; 351(9114): 1467-71.
50. Smeeth L, Thomas SL, Hall AJ, et al. Risk of myocardial infarction and stroke
after acute infection or vaccination. New England Journal of Medicine 2004;
351(25):2611-8.
51. Corrales-Medina VF, Musher DM, Wells GA, et al. Cardiac complications in
patients with community-acquired pneumonia: Incidence, timing, risk factors,
and association with short-term mortality. Circulation. 2012; 125:773-781.
[PubMed: 22219349]
52. Corrales-Medina VF, Musher DM. Immunomodulatory agents in the treatment of
community- acquired pneumonia: a systematic review. J Infect. 2011; 63(3): 187199. [PubMed: 21763343]
53. Emsley HC, Hopkins SJ. Acute ischaemic stroke and infection: Recent and
emerging concepts. Lancet Neurol. 2008; 7(4):341-353. [PubMed: 18339349]
54. Dong M, Liu T, Li G. Association between acute infections and risk of acute
coronary syndrome: A meta-analysis. Int J Cardiol. 2011; 147(3):479-482.
[PubMed: 21296437]
55. Singanayagam A, Elder DH, Chalmers JD. Is community acquired pneumonia an
independent risk factor for cardiovascular disease? European Respiration
Journal, 2012. 39(l):187-96
84

Bibliography
56. Berk BC, Weintraub WS, Alexander RW. Elevation of C- reactive protein in
"active" coronary artery disease. Am J Cardiol 1990; 65(3): 168-72.
57. Mendall MA, Patel P, Ballam L, et al. C reactive protein and its relation to
cardiovascular risk factors: a population based cross-sectional study. BMJ 1996;
312:1061-5.
58. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of
cardiovascular disease in apparently healthy men. N Engl J Med. 1997; 336:973-9.
59. De Graff AC, Travell JG, Yager JA. An electrocardiographic study of the heart in
lobar pneumonia. J Clin Invest 1931; 10(3):633-51.
60. Master AM, Romamoff A, Jaffe H. Electrocardiographic changes in pneumonia.
Am Heart J 1931; 6:696-709.
61. Thomson KJ, Rustein DD, Tolmac DM, et al. Electrocardiographic studies
during and after pneumococcus pneumonia. Am Heart J 1946;31:565-79
62. Ferro G, Duilio C, Spinelli L, et al. Relation between diastolic perfusion time and
coronary artery stenosis during stress induced myocardial ischaemia. Circulation
1995; 92(3):342-7.
63. Merkus D, Kajiya F, Vink H, et al. Prolonged diastolic time fraction protects
myocardial perfusion when coronary blood flow is reduced. Circulation 1999; 100:
75-81.
64. Friedberg CK. Diseases of the Heart; 3rd edition. Philadelphia: W.B. Saunders;
1966: p: 648.
65. Wattigney WA, Mensah GA, Croft JB. Increasing trends in hospitalization for
atrial fibrillation in the United States 1985 through 1999: Implications for
primary prevention. Circulation 2003; 108:711-6.
66. Muller JE. Circadian variation and triggering of acute coronary events. Am Heart
J. 1999; 137:Sl-8.
67. Kloner RA. Natural and unnatural triggers of myocardial infarction. Prognostic
Cardiovascular Disease. 2006; 48(4):285-300.
68. Mittleman MA, Maclure M, Tofler GH, et al. Triggering of acute myocardial
infarction by heavy physical exertion: protection against triggering by regular
exertion. Determinants of Myocardial Infarction Onset Study Investigators. New
England Journal of Medicine. 1993; 329(23): 1677-83.
69. Willich SN, Lewis M, Lowel H, et al. Physical exertion as a trigger of acute
myocardial infarction. Triggers and Mechanisms of Myocardial Infarction Study
Group. New England Journal of Medicine. 1993; 329(23): 1684-90.
85

Bibliography
70. Giri S, Thompson PD, Kiernan FJ, et al. Clinical and angiographic characteristics
of exertion- related acute myocardial infarction. JAMA 1999; 282(18):1731-6.
71. Danesh J, Collins R, Appleby P, et al. Association of fibrinogen, C reactive
protein, albumin or leukocyte counts with coronary heart disease: meta-analyses
of prospective studies. JAMA 1998; 279(18): 1477-82.
72. Mendall MA, Patel P, Asante M, et al. Relation of serum cytokine concentrations to
cardiovascular risk factors and coronary heart disease. Heart 1997;78(3):273-7
73. Kumar A, Thota V, Dee L, et al. Tumor necrosis factor alpha and interleukin l
beta are responsible for in vitro myocardial cell depression induced by human
septic shock serum. J Exp Med 1996; 183(3):949-58.
74. Mann DL. Inflammatory mediators and the failing heart: past, present, and the
foreseeable future. Circulation Res 2002; 91(11):988-98.
75. Alber DG, Powell KL, Vallance P, et al. Herpesvirus infection accelerates
atherosclerosis

in

the

apolipoprotein

deficient

mouse.

Circulation

2000;102:779-85
76. Lindahl B, Toss H, Siegbahn A, et al. Markers of myocardial damage and
inflammation in relation to long term mortality in unstable coronary artery
disease. N Engl J Med. 2000; 343:1139-47.
77.

Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other
circulating markers of inflammation in the prediction of coronary heart disease.
N Engl J Med. 2004; 350:1387-97.

78.

Keaney JF, Vita JA. The value of inflammation for predicting unstable angina. N
Engl J Med. 2002; 347:55-7.

79.

Brennan ML, Penn MS, Van Lente FV, et al. Prognostic value of myeloperoxidase
in patients with chest pain. N Engl J Med. 2003; 349:1595-1604.

80. Dutt TS, Tousheed SZ and Mohan BV M. Community Acquired Pneumonia and
Cardiac Diseases: A Fatal Association. Indian J Chest Dis Allied Sciences. 2014;
56:153-156.
81. Musher DM, Rueda AM, Kaka AS, et al. The Association between
Pneumococcal Pneumonia and Acute Cardiac Events. Clinical Infectious
Diseases 2007; 45:158-65.
82. Viasus D, Vidal CG, Manresa F, et al.. Risk stratification and prognosis of acute
cardiac events in hospitalised adults with CAP. Journal of infection, 2013, 66(1):
27-33
86

Bibliography
83. Mandal P, Chalmers JD, Choudhury G, et al. Vascular complications are
associated with poor outcome in CAP. QJM 2011; 104(6): 489-95.
84. Menendez R, Sahuquillo-Arce JM, Reyes S, et al. Cytokine activation patterns
and biomarkers are influenced by microorganisms in CAP. Chest 2012, 141(6):
1537-45
85. Foley RN, Parfrey PS, Harnett JD, et al. Hypoalbuminemia, cardiac morbidity
and mortality in end stage renal disease. J Am Society of Nephrology 1996; 7(5):
728-36.
86. Smeeth L, Thomas SL, Hall AJ, et al. Risk of Myocardial Infarction and Stroke
after Acute Infection or Vaccination. N Engl J Med. 2004; 351 :2611-2618.
87. Griffin AT, Wiemken TL, Arnold FW. Risk factors for cardiovascular events in
hospitalized patients with Community Acquired Pneumonia. International
Journal of Infectious Disease, 2013, Dec; 17(12):el 125-1129.
88. Crain MC, Breidthardt T, Stolz D, et al. Use of B-type natriuretic peptide in the
risk stratification of community acquired pneumonia. J Intern Med, 2008, 264:
166-176.
89. Jeong KY, Kim K, Kim TY, et al. Prognostic value of N- terminal pro-brain
natriuretic peptide in hospitalised patients with community- acquired
pneumonia. Emerg Med J. 2011. 28: 122-127.
90. Ilva TJ, Eskola MJ, Nikus KC, et al. The etiology and prognostic significance of
cardiac troponin I elevation in unselected emergency department patients. J
Emerg Med, 2010, 38(1): 1-5.
91. Lee YJ, Lee H, Park JS, et al. Cardiac troponin I as a prognostic factor in
critically ill pneumonia patients in the absence of acute coronary syndrome.
Journal of Critical care, 2014, 0883- 9441(14)00490-0, Pubmed.
92. Chang CL, Mills GD, Karalus NC, et al. Biomarkers of Cardiac Dysfunction and
Mortality from Community Acquired Pneumonia in Adults. PLOS one, 2013,
8(5): e62612.
93. Kuller LH, Tracy RP, Shaten J, et al. Relation of C reactive protein and coronary
heart disease in the MRFIT nested case control study: Multiple Risk Factor
Intervention Trial. Am J Epidemiol 1996; 144(6): 537-47.
94. Ridker PM, Cushman M, Stampfer MJ, et al, Hennekens CH. Inflammation,
aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl
J Med. 1997; 336:973-9.
87

Bibliography
95. Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C-reactive
protein and serum amyloid a protein in severe unstable angina. New Engl J Med
1994; 331:417-424.
96. Haverkate F, Thompson SG, Pyke SD, et al. Production of C-reactive protein and
risk of coronary events in stable and unstable angina: European Concerted
Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet
1997;349(9050):462-6
97. Seedat MA, Feldman C, Skouliragia J, et al. A study of community acquired
pneumonia, including the details of cardiac changes. Q JMed,.1993,Oct;86(10):
669-675.
98. Stone A FM, Mendall MA, Kaski JC, et al. Effect of Treatment for Chlamydia
pneumoniae and Helicobacter pylori on Markers of Inflammation and Cardiac
Events in Patients with Acute Coronary Syndrome. South Thames Trial of
Antibiotics in Myocardial Infarction and Unstable Angina (STAMINA).
Circulation. 2002; 106:1219-1223.
99. Cangemi R, Casciaro M, Rossi E, et al. Platelet activation is Associated with
Myocardial Infarction in Patients with Pneumonia. J Am Coll Cardiol. 2014;
64(18): 1917-1925. Eurich DT, Johnstone JJ, Sandhu JKM, et al. Pneumococcal
vaccination and risk of acute coronary syndromes in patients with pneumonia:
population-based cohort study. Heart 2012; 98: 1072-1077.
100. Eurich DT, Johnstone JJ, Sandhu JKM, et al. Pneumococcal vaccination and
risk of acute coronary syndromes in patients with pneumonia: population-based
cohort study. Heart 2012; 98: 1072-1077
101. Aliberti S, Amir A, Peyrani P, et al. Incidence, Etiology, Timing, and Risk
Factors for Clinical Failure in Hospitalized Patients With Community Acquired
Pneumonia. Chest 2008; 134(5):955-962.
102. Aspa J. The Future Is Now in Community Acquired Pneumonia:
Cardiovascular Complications and Conjugate Vaccines. J. Aspa/ Arch
Bronconeumol. 2012; 48(10):347-348.
103. Wu A, Good C, Downs JR, et al. The Association of Cardio protective
Medications with Pneumonia Related Outcomes. 2014, PLoS one 9(1): e85797.
104. Hallqvist J, Moller J, Ahlbom A, et al. Does heavy physical exertion trigger
myocardial infarction? A case- crossover analysis nested in a population based
case referent study. Am J Epidemiology 2000, Mar 1; 151(5):459-67.
88

Bibliography
105. Shah BA, Ahmed W, Dhobi GN, et al. Validity of Pneumonia Severity Index
and CURB-65 Severity Scoring Systems in Community Acquired Pneumonia in
an Indian Setting. Indian J Chest Dis Allied Sci 2010; 52:9-17.
106. Wilson PW, D'Agostino RB, Levy D, et al. Prediction of Coronary heart
disease using risk factor categories. Circulation. 1998:97:1837-1847.
107. Wilson PW. Diabetes mellitus and coronary heart disease. Am J Kidney Dis.
1998:32:S89- S100.
108. McGill HC Jr, McMahan CA. Determinants of atherosclerosis in the young:
Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research
Group. Am J Cardiol. 1998:82:30T- 36T.
109. US Dept of Health and Human services. Reducing the Health Consequences of
Smoking: 25 years of Progress. A report of the Surgeon General. US Department
of Health and Human Services, Public Health Service, Centres for Disease
Control, Centre for Chronic disease Prevention and Health Promotion, Office on
Smoking And Health; 1989. DHHS Publication (CDC) 89-8411.
110. US Dept of Health and Human Services. The Health Benefits of Smoking
Cessation. A Report of the Surgeon General USDHHS, Centres for Disease
Control. Office of Smoking and Health; 1990 DHHS Publication (CDC) 908416.
111. Piano MR, Benowitz NL, FitzGerald GA, et al. Impact of smokeless Tobacco
Products on Cardiovascular Disease: Implications for Policy, Prevention and
Treatment. A Policy statement from the American Heart Association.
Circulation. 2010; 122: 1520-1544.
112. Vestbo

J. The TORCH (Towards a Revolution in COPD Health) Survival

protocol. The TORCH Study Group. Eur Respir J; 2004; 24: 206-210.

89